Global Nuclear Medicine Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Summary
Nuclear Medicine?or Radiopharmaceuticals? are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
According to APO Research, The global Nuclear Medicine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Nuclear Medicine include GE Healthcare, Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging, Bayer, Triad Isotopes, Nordion, Jubilant Pharma and Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Nuclear Medicine, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Nuclear Medicine, also provides the value of main regions and countries. Of the upcoming market potential for Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nuclear Medicine revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Nuclear Medicine company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Nuclear Medicine segment by Company
1. To analyze and research the global Nuclear Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Nuclear Medicine key companies, revenue, market share, and recent developments.
3. To split the Nuclear Medicine breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Nuclear Medicine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Nuclear Medicine significant trends, drivers, influence factors in global and regions.
6. To analyze Nuclear Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Medicine industry.
Chapter 3: Detailed analysis of Nuclear Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Nuclear Medicine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Nuclear Medicine?or Radiopharmaceuticals? are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
According to APO Research, The global Nuclear Medicine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Nuclear Medicine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Nuclear Medicine include GE Healthcare, Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging, Bayer, Triad Isotopes, Nordion, Jubilant Pharma and Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Nuclear Medicine, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Nuclear Medicine, also provides the value of main regions and countries. Of the upcoming market potential for Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nuclear Medicine revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Nuclear Medicine company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Nuclear Medicine segment by Company
- GE Healthcare
- Bracco Imaging
- Mallinckrodt
- Lantheus Medical Imaging
- Bayer
- Triad Isotopes
- Nordion
- Jubilant Pharma
- Eli Lilly
- SIEMENS
- China Isotope & Radiation
- Dongcheng
- Tc-99
- I-123/131
- In-111
- Xe-133
- Th-201
- Ga-67
- Others
- Diagnostic
- Therapeutic
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Nuclear Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Nuclear Medicine key companies, revenue, market share, and recent developments.
3. To split the Nuclear Medicine breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Nuclear Medicine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Nuclear Medicine significant trends, drivers, influence factors in global and regions.
6. To analyze Nuclear Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Medicine industry.
Chapter 3: Detailed analysis of Nuclear Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Nuclear Medicine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Nuclear Medicine Market Size, 2019 VS 2023 VS 2030
1.3 Global Nuclear Medicine Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 NUCLEAR MEDICINE MARKET DYNAMICS
2.1 Nuclear Medicine Industry Trends
2.2 Nuclear Medicine Industry Drivers
2.3 Nuclear Medicine Industry Opportunities and Challenges
2.4 Nuclear Medicine Industry Restraints
3 NUCLEAR MEDICINE MARKET BY COMPANY
3.1 Global Nuclear Medicine Company Revenue Ranking in 2023
3.2 Global Nuclear Medicine Revenue by Company (2019-2024)
3.3 Global Nuclear Medicine Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Nuclear Medicine Company Manufacturing Base & Headquarters
3.5 Global Nuclear Medicine Company, Product Type & Application
3.6 Global Nuclear Medicine Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Nuclear Medicine Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Nuclear Medicine Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 NUCLEAR MEDICINE MARKET BY TYPE
4.1 Nuclear Medicine Type Introduction
4.1.1 Tc-99
4.1.2 I-123/131
4.1.3 In-111
4.1.4 Xe-133
4.1.5 Th-201
4.1.6 Ga-67
4.1.7 Others
4.2 Global Nuclear Medicine Sales Value by Type
4.2.1 Global Nuclear Medicine Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Nuclear Medicine Sales Value by Type (2019-2030)
4.2.3 Global Nuclear Medicine Sales Value Share by Type (2019-2030)
5 NUCLEAR MEDICINE MARKET BY APPLICATION
5.1 Nuclear Medicine Application Introduction
5.1.1 Diagnostic
5.1.2 Therapeutic
5.2 Global Nuclear Medicine Sales Value by Application
5.2.1 Global Nuclear Medicine Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Nuclear Medicine Sales Value by Application (2019-2030)
5.2.3 Global Nuclear Medicine Sales Value Share by Application (2019-2030)
6 NUCLEAR MEDICINE MARKET BY REGION
6.1 Global Nuclear Medicine Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Nuclear Medicine Sales Value by Region (2019-2030)
6.2.1 Global Nuclear Medicine Sales Value by Region: 2019-2024
6.2.2 Global Nuclear Medicine Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Nuclear Medicine Sales Value (2019-2030)
6.3.2 North America Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Nuclear Medicine Sales Value (2019-2030)
6.4.2 Europe Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Nuclear Medicine Sales Value (2019-2030)
6.5.2 Asia-Pacific Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Nuclear Medicine Sales Value (2019-2030)
6.6.2 Latin America Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Nuclear Medicine Sales Value (2019-2030)
6.7.2 Middle East & Africa Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
7 NUCLEAR MEDICINE MARKET BY COUNTRY
7.1 Global Nuclear Medicine Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Nuclear Medicine Sales Value by Country (2019-2030)
7.2.1 Global Nuclear Medicine Sales Value by Country (2019-2024)
7.2.2 Global Nuclear Medicine Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.3.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.4.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.5.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.6.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.7.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.8.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.9.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.10.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.11.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.12.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.13.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.14.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.15.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.16.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.17.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.18.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.19.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.20.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.21.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 GE Healthcare
8.1.1 GE Healthcare Comapny Information
8.1.2 GE Healthcare Business Overview
8.1.3 GE Healthcare Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.1.4 GE Healthcare Nuclear Medicine Product Portfolio
8.1.5 GE Healthcare Recent Developments
8.2 Bracco Imaging
8.2.1 Bracco Imaging Comapny Information
8.2.2 Bracco Imaging Business Overview
8.2.3 Bracco Imaging Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.2.4 Bracco Imaging Nuclear Medicine Product Portfolio
8.2.5 Bracco Imaging Recent Developments
8.3 Mallinckrodt
8.3.1 Mallinckrodt Comapny Information
8.3.2 Mallinckrodt Business Overview
8.3.3 Mallinckrodt Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.3.4 Mallinckrodt Nuclear Medicine Product Portfolio
8.3.5 Mallinckrodt Recent Developments
8.4 Lantheus Medical Imaging
8.4.1 Lantheus Medical Imaging Comapny Information
8.4.2 Lantheus Medical Imaging Business Overview
8.4.3 Lantheus Medical Imaging Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.4.4 Lantheus Medical Imaging Nuclear Medicine Product Portfolio
8.4.5 Lantheus Medical Imaging Recent Developments
8.5 Bayer
8.5.1 Bayer Comapny Information
8.5.2 Bayer Business Overview
8.5.3 Bayer Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.5.4 Bayer Nuclear Medicine Product Portfolio
8.5.5 Bayer Recent Developments
8.6 Triad Isotopes
8.6.1 Triad Isotopes Comapny Information
8.6.2 Triad Isotopes Business Overview
8.6.3 Triad Isotopes Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.6.4 Triad Isotopes Nuclear Medicine Product Portfolio
8.6.5 Triad Isotopes Recent Developments
8.7 Nordion
8.7.1 Nordion Comapny Information
8.7.2 Nordion Business Overview
8.7.3 Nordion Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.7.4 Nordion Nuclear Medicine Product Portfolio
8.7.5 Nordion Recent Developments
8.8 Jubilant Pharma
8.8.1 Jubilant Pharma Comapny Information
8.8.2 Jubilant Pharma Business Overview
8.8.3 Jubilant Pharma Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.8.4 Jubilant Pharma Nuclear Medicine Product Portfolio
8.8.5 Jubilant Pharma Recent Developments
8.9 Eli Lilly
8.9.1 Eli Lilly Comapny Information
8.9.2 Eli Lilly Business Overview
8.9.3 Eli Lilly Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.9.4 Eli Lilly Nuclear Medicine Product Portfolio
8.9.5 Eli Lilly Recent Developments
8.10 SIEMENS
8.10.1 SIEMENS Comapny Information
8.10.2 SIEMENS Business Overview
8.10.3 SIEMENS Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.10.4 SIEMENS Nuclear Medicine Product Portfolio
8.10.5 SIEMENS Recent Developments
8.11 China Isotope & Radiation
8.11.1 China Isotope & Radiation Comapny Information
8.11.2 China Isotope & Radiation Business Overview
8.11.3 China Isotope & Radiation Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.11.4 China Isotope & Radiation Nuclear Medicine Product Portfolio
8.11.5 China Isotope & Radiation Recent Developments
8.12 Dongcheng
8.12.1 Dongcheng Comapny Information
8.12.2 Dongcheng Business Overview
8.12.3 Dongcheng Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.12.4 Dongcheng Nuclear Medicine Product Portfolio
8.12.5 Dongcheng Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
1.1 Product Definition
1.2 Global Nuclear Medicine Market Size, 2019 VS 2023 VS 2030
1.3 Global Nuclear Medicine Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 NUCLEAR MEDICINE MARKET DYNAMICS
2.1 Nuclear Medicine Industry Trends
2.2 Nuclear Medicine Industry Drivers
2.3 Nuclear Medicine Industry Opportunities and Challenges
2.4 Nuclear Medicine Industry Restraints
3 NUCLEAR MEDICINE MARKET BY COMPANY
3.1 Global Nuclear Medicine Company Revenue Ranking in 2023
3.2 Global Nuclear Medicine Revenue by Company (2019-2024)
3.3 Global Nuclear Medicine Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Nuclear Medicine Company Manufacturing Base & Headquarters
3.5 Global Nuclear Medicine Company, Product Type & Application
3.6 Global Nuclear Medicine Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Nuclear Medicine Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Nuclear Medicine Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 NUCLEAR MEDICINE MARKET BY TYPE
4.1 Nuclear Medicine Type Introduction
4.1.1 Tc-99
4.1.2 I-123/131
4.1.3 In-111
4.1.4 Xe-133
4.1.5 Th-201
4.1.6 Ga-67
4.1.7 Others
4.2 Global Nuclear Medicine Sales Value by Type
4.2.1 Global Nuclear Medicine Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Nuclear Medicine Sales Value by Type (2019-2030)
4.2.3 Global Nuclear Medicine Sales Value Share by Type (2019-2030)
5 NUCLEAR MEDICINE MARKET BY APPLICATION
5.1 Nuclear Medicine Application Introduction
5.1.1 Diagnostic
5.1.2 Therapeutic
5.2 Global Nuclear Medicine Sales Value by Application
5.2.1 Global Nuclear Medicine Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Nuclear Medicine Sales Value by Application (2019-2030)
5.2.3 Global Nuclear Medicine Sales Value Share by Application (2019-2030)
6 NUCLEAR MEDICINE MARKET BY REGION
6.1 Global Nuclear Medicine Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Nuclear Medicine Sales Value by Region (2019-2030)
6.2.1 Global Nuclear Medicine Sales Value by Region: 2019-2024
6.2.2 Global Nuclear Medicine Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Nuclear Medicine Sales Value (2019-2030)
6.3.2 North America Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Nuclear Medicine Sales Value (2019-2030)
6.4.2 Europe Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Nuclear Medicine Sales Value (2019-2030)
6.5.2 Asia-Pacific Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Nuclear Medicine Sales Value (2019-2030)
6.6.2 Latin America Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Nuclear Medicine Sales Value (2019-2030)
6.7.2 Middle East & Africa Nuclear Medicine Sales Value Share by Country, 2023 VS 2030
7 NUCLEAR MEDICINE MARKET BY COUNTRY
7.1 Global Nuclear Medicine Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Nuclear Medicine Sales Value by Country (2019-2030)
7.2.1 Global Nuclear Medicine Sales Value by Country (2019-2024)
7.2.2 Global Nuclear Medicine Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.3.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.4.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.5.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.6.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.7.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.8.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.9.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.10.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.11.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.12.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.13.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.14.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.15.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.16.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.17.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.18.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.19.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.20.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Nuclear Medicine Sales Value Growth Rate (2019-2030)
7.21.2 Global Nuclear Medicine Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Nuclear Medicine Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 GE Healthcare
8.1.1 GE Healthcare Comapny Information
8.1.2 GE Healthcare Business Overview
8.1.3 GE Healthcare Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.1.4 GE Healthcare Nuclear Medicine Product Portfolio
8.1.5 GE Healthcare Recent Developments
8.2 Bracco Imaging
8.2.1 Bracco Imaging Comapny Information
8.2.2 Bracco Imaging Business Overview
8.2.3 Bracco Imaging Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.2.4 Bracco Imaging Nuclear Medicine Product Portfolio
8.2.5 Bracco Imaging Recent Developments
8.3 Mallinckrodt
8.3.1 Mallinckrodt Comapny Information
8.3.2 Mallinckrodt Business Overview
8.3.3 Mallinckrodt Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.3.4 Mallinckrodt Nuclear Medicine Product Portfolio
8.3.5 Mallinckrodt Recent Developments
8.4 Lantheus Medical Imaging
8.4.1 Lantheus Medical Imaging Comapny Information
8.4.2 Lantheus Medical Imaging Business Overview
8.4.3 Lantheus Medical Imaging Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.4.4 Lantheus Medical Imaging Nuclear Medicine Product Portfolio
8.4.5 Lantheus Medical Imaging Recent Developments
8.5 Bayer
8.5.1 Bayer Comapny Information
8.5.2 Bayer Business Overview
8.5.3 Bayer Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.5.4 Bayer Nuclear Medicine Product Portfolio
8.5.5 Bayer Recent Developments
8.6 Triad Isotopes
8.6.1 Triad Isotopes Comapny Information
8.6.2 Triad Isotopes Business Overview
8.6.3 Triad Isotopes Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.6.4 Triad Isotopes Nuclear Medicine Product Portfolio
8.6.5 Triad Isotopes Recent Developments
8.7 Nordion
8.7.1 Nordion Comapny Information
8.7.2 Nordion Business Overview
8.7.3 Nordion Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.7.4 Nordion Nuclear Medicine Product Portfolio
8.7.5 Nordion Recent Developments
8.8 Jubilant Pharma
8.8.1 Jubilant Pharma Comapny Information
8.8.2 Jubilant Pharma Business Overview
8.8.3 Jubilant Pharma Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.8.4 Jubilant Pharma Nuclear Medicine Product Portfolio
8.8.5 Jubilant Pharma Recent Developments
8.9 Eli Lilly
8.9.1 Eli Lilly Comapny Information
8.9.2 Eli Lilly Business Overview
8.9.3 Eli Lilly Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.9.4 Eli Lilly Nuclear Medicine Product Portfolio
8.9.5 Eli Lilly Recent Developments
8.10 SIEMENS
8.10.1 SIEMENS Comapny Information
8.10.2 SIEMENS Business Overview
8.10.3 SIEMENS Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.10.4 SIEMENS Nuclear Medicine Product Portfolio
8.10.5 SIEMENS Recent Developments
8.11 China Isotope & Radiation
8.11.1 China Isotope & Radiation Comapny Information
8.11.2 China Isotope & Radiation Business Overview
8.11.3 China Isotope & Radiation Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.11.4 China Isotope & Radiation Nuclear Medicine Product Portfolio
8.11.5 China Isotope & Radiation Recent Developments
8.12 Dongcheng
8.12.1 Dongcheng Comapny Information
8.12.2 Dongcheng Business Overview
8.12.3 Dongcheng Nuclear Medicine Revenue and Gross Margin (2019-2024)
8.12.4 Dongcheng Nuclear Medicine Product Portfolio
8.12.5 Dongcheng Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
LIST OF TABLES
Table 1. Nuclear Medicine Industry Trends
Table 2. Nuclear Medicine Industry Drivers
Table 3. Nuclear Medicine Industry Opportunities and Challenges
Table 4. Nuclear Medicine Industry Restraints
Table 5. Global Nuclear Medicine Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Nuclear Medicine Revenue Share by Company (2019-2024)
Table 7. Global Nuclear Medicine Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Nuclear Medicine Key Company Manufacturing Base & Headquarters
Table 9. Global Nuclear Medicine Company, Product Type & Application
Table 10. Global Nuclear Medicine Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Nuclear Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Tc-99
Table 15. Major Companies of I-123/131
Table 16. Major Companies of In-111
Table 17. Major Companies of Xe-133
Table 18. Major Companies of Th-201
Table 19. Major Companies of Ga-67
Table 20. Major Companies of Others
Table 21. Global Nuclear Medicine Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 22. Global Nuclear Medicine Sales Value by Type (2019-2024) & (US$ Million)
Table 23. Global Nuclear Medicine Sales Value by Type (2025-2030) & (US$ Million)
Table 24. Global Nuclear Medicine Sales Value Share by Type (2019-2024)
Table 25. Global Nuclear Medicine Sales Value Share by Type (2025-2030)
Table 26. Major Companies of Diagnostic
Table 27. Major Companies of Therapeutic
Table 28. Global Nuclear Medicine Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Nuclear Medicine Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Nuclear Medicine Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Nuclear Medicine Sales Value Share by Application (2019-2024)
Table 32. Global Nuclear Medicine Sales Value Share by Application (2025-2030)
Table 33. Global Nuclear Medicine Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 34. Global Nuclear Medicine Sales Value by Region (2019-2024) & (US$ Million)
Table 35. Global Nuclear Medicine Sales Value Share by Region (2019-2024)
Table 36. Global Nuclear Medicine Sales Value by Region (2025-2030) & (US$ Million)
Table 37. Global Nuclear Medicine Sales Value Share by Region (2025-2030)
Table 38. Global Nuclear Medicine Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 39. Global Nuclear Medicine Sales Value by Country (2019-2024) & (US$ Million)
Table 40. Global Nuclear Medicine Sales Value Market Share by Country (2019-2024)
Table 41. Global Nuclear Medicine Sales Value by Country (2025-2030) & (US$ Million)
Table 42. Global Nuclear Medicine Sales Value Market Share by Country (2025-2030)
Table 43. GE Healthcare Company Information
Table 44. GE Healthcare Business Overview
Table 45. GE Healthcare Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 46. GE Healthcare Nuclear Medicine Product Portfolio
Table 47. GE Healthcare Recent Development
Table 48. Bracco Imaging Company Information
Table 49. Bracco Imaging Business Overview
Table 50. Bracco Imaging Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 51. Bracco Imaging Nuclear Medicine Product Portfolio
Table 52. Bracco Imaging Recent Development
Table 53. Mallinckrodt Company Information
Table 54. Mallinckrodt Business Overview
Table 55. Mallinckrodt Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 56. Mallinckrodt Nuclear Medicine Product Portfolio
Table 57. Mallinckrodt Recent Development
Table 58. Lantheus Medical Imaging Company Information
Table 59. Lantheus Medical Imaging Business Overview
Table 60. Lantheus Medical Imaging Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 61. Lantheus Medical Imaging Nuclear Medicine Product Portfolio
Table 62. Lantheus Medical Imaging Recent Development
Table 63. Bayer Company Information
Table 64. Bayer Business Overview
Table 65. Bayer Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 66. Bayer Nuclear Medicine Product Portfolio
Table 67. Bayer Recent Development
Table 68. Triad Isotopes Company Information
Table 69. Triad Isotopes Business Overview
Table 70. Triad Isotopes Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 71. Triad Isotopes Nuclear Medicine Product Portfolio
Table 72. Triad Isotopes Recent Development
Table 73. Nordion Company Information
Table 74. Nordion Business Overview
Table 75. Nordion Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 76. Nordion Nuclear Medicine Product Portfolio
Table 77. Nordion Recent Development
Table 78. Jubilant Pharma Company Information
Table 79. Jubilant Pharma Business Overview
Table 80. Jubilant Pharma Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 81. Jubilant Pharma Nuclear Medicine Product Portfolio
Table 82. Jubilant Pharma Recent Development
Table 83. Eli Lilly Company Information
Table 84. Eli Lilly Business Overview
Table 85. Eli Lilly Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 86. Eli Lilly Nuclear Medicine Product Portfolio
Table 87. Eli Lilly Recent Development
Table 88. SIEMENS Company Information
Table 89. SIEMENS Business Overview
Table 90. SIEMENS Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 91. SIEMENS Nuclear Medicine Product Portfolio
Table 92. SIEMENS Recent Development
Table 93. China Isotope & Radiation Company Information
Table 94. China Isotope & Radiation Business Overview
Table 95. China Isotope & Radiation Nuclear Medicine Sales (M Dose), Value (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 96. China Isotope & Radiation Nuclear Medicine Product Portfolio
Table 97. China Isotope & Radiation Recent Development
Table 98. Dongcheng Company Information
Table 99. Dongcheng Business Overview
Table 100. Dongcheng Nuclear Medicine Sales (M Dose), Value (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 101. Dongcheng Nuclear Medicine Product Portfolio
Table 102. Dongcheng Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Authors List of This Report
Table 105. Secondary Sources
Table 106. Primary Sources
Table 1. Nuclear Medicine Industry Trends
Table 2. Nuclear Medicine Industry Drivers
Table 3. Nuclear Medicine Industry Opportunities and Challenges
Table 4. Nuclear Medicine Industry Restraints
Table 5. Global Nuclear Medicine Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Nuclear Medicine Revenue Share by Company (2019-2024)
Table 7. Global Nuclear Medicine Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Nuclear Medicine Key Company Manufacturing Base & Headquarters
Table 9. Global Nuclear Medicine Company, Product Type & Application
Table 10. Global Nuclear Medicine Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Nuclear Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Tc-99
Table 15. Major Companies of I-123/131
Table 16. Major Companies of In-111
Table 17. Major Companies of Xe-133
Table 18. Major Companies of Th-201
Table 19. Major Companies of Ga-67
Table 20. Major Companies of Others
Table 21. Global Nuclear Medicine Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 22. Global Nuclear Medicine Sales Value by Type (2019-2024) & (US$ Million)
Table 23. Global Nuclear Medicine Sales Value by Type (2025-2030) & (US$ Million)
Table 24. Global Nuclear Medicine Sales Value Share by Type (2019-2024)
Table 25. Global Nuclear Medicine Sales Value Share by Type (2025-2030)
Table 26. Major Companies of Diagnostic
Table 27. Major Companies of Therapeutic
Table 28. Global Nuclear Medicine Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Nuclear Medicine Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Nuclear Medicine Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Nuclear Medicine Sales Value Share by Application (2019-2024)
Table 32. Global Nuclear Medicine Sales Value Share by Application (2025-2030)
Table 33. Global Nuclear Medicine Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 34. Global Nuclear Medicine Sales Value by Region (2019-2024) & (US$ Million)
Table 35. Global Nuclear Medicine Sales Value Share by Region (2019-2024)
Table 36. Global Nuclear Medicine Sales Value by Region (2025-2030) & (US$ Million)
Table 37. Global Nuclear Medicine Sales Value Share by Region (2025-2030)
Table 38. Global Nuclear Medicine Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 39. Global Nuclear Medicine Sales Value by Country (2019-2024) & (US$ Million)
Table 40. Global Nuclear Medicine Sales Value Market Share by Country (2019-2024)
Table 41. Global Nuclear Medicine Sales Value by Country (2025-2030) & (US$ Million)
Table 42. Global Nuclear Medicine Sales Value Market Share by Country (2025-2030)
Table 43. GE Healthcare Company Information
Table 44. GE Healthcare Business Overview
Table 45. GE Healthcare Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 46. GE Healthcare Nuclear Medicine Product Portfolio
Table 47. GE Healthcare Recent Development
Table 48. Bracco Imaging Company Information
Table 49. Bracco Imaging Business Overview
Table 50. Bracco Imaging Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 51. Bracco Imaging Nuclear Medicine Product Portfolio
Table 52. Bracco Imaging Recent Development
Table 53. Mallinckrodt Company Information
Table 54. Mallinckrodt Business Overview
Table 55. Mallinckrodt Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 56. Mallinckrodt Nuclear Medicine Product Portfolio
Table 57. Mallinckrodt Recent Development
Table 58. Lantheus Medical Imaging Company Information
Table 59. Lantheus Medical Imaging Business Overview
Table 60. Lantheus Medical Imaging Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 61. Lantheus Medical Imaging Nuclear Medicine Product Portfolio
Table 62. Lantheus Medical Imaging Recent Development
Table 63. Bayer Company Information
Table 64. Bayer Business Overview
Table 65. Bayer Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 66. Bayer Nuclear Medicine Product Portfolio
Table 67. Bayer Recent Development
Table 68. Triad Isotopes Company Information
Table 69. Triad Isotopes Business Overview
Table 70. Triad Isotopes Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 71. Triad Isotopes Nuclear Medicine Product Portfolio
Table 72. Triad Isotopes Recent Development
Table 73. Nordion Company Information
Table 74. Nordion Business Overview
Table 75. Nordion Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 76. Nordion Nuclear Medicine Product Portfolio
Table 77. Nordion Recent Development
Table 78. Jubilant Pharma Company Information
Table 79. Jubilant Pharma Business Overview
Table 80. Jubilant Pharma Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 81. Jubilant Pharma Nuclear Medicine Product Portfolio
Table 82. Jubilant Pharma Recent Development
Table 83. Eli Lilly Company Information
Table 84. Eli Lilly Business Overview
Table 85. Eli Lilly Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 86. Eli Lilly Nuclear Medicine Product Portfolio
Table 87. Eli Lilly Recent Development
Table 88. SIEMENS Company Information
Table 89. SIEMENS Business Overview
Table 90. SIEMENS Nuclear Medicine Revenue (US$ Million) and Gross Margin (2019-2024)
Table 91. SIEMENS Nuclear Medicine Product Portfolio
Table 92. SIEMENS Recent Development
Table 93. China Isotope & Radiation Company Information
Table 94. China Isotope & Radiation Business Overview
Table 95. China Isotope & Radiation Nuclear Medicine Sales (M Dose), Value (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 96. China Isotope & Radiation Nuclear Medicine Product Portfolio
Table 97. China Isotope & Radiation Recent Development
Table 98. Dongcheng Company Information
Table 99. Dongcheng Business Overview
Table 100. Dongcheng Nuclear Medicine Sales (M Dose), Value (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 101. Dongcheng Nuclear Medicine Product Portfolio
Table 102. Dongcheng Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Authors List of This Report
Table 105. Secondary Sources
Table 106. Primary Sources
LIST OF FIGURES
Figure 1. Nuclear Medicine Product Picture
Figure 2. Global Nuclear Medicine Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Nuclear Medicine Market Size (2019-2030) & (US$ Million)
Figure 4. Global Nuclear Medicine Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Tc-99 Picture
Figure 8. I-123/131 Picture
Figure 9. In-111 Picture
Figure 10. Xe-133 Picture
Figure 11. Th-201 Picture
Figure 12. Ga-67 Picture
Figure 13. Others Picture
Figure 14. Global Nuclear Medicine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Nuclear Medicine Sales Value Share 2019 VS 2023 VS 2030
Figure 16. Global Nuclear Medicine Sales Value Share by Type (2019-2030)
Figure 17. Diagnostic Picture
Figure 18. Therapeutic Picture
Figure 19. Global Nuclear Medicine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global Nuclear Medicine Sales Value Share 2019 VS 2023 VS 2030
Figure 21. Global Nuclear Medicine Sales Value Share by Application (2019-2030)
Figure 22. Global Nuclear Medicine Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 23. Global Nuclear Medicine Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 24. North America Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 25. North America Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 26. Europe Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 27. Europe Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Asia-Pacific Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 30. Latin America Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 31. Latin America Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 32. Middle East & Africa Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 33. Middle East & Africa Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 34. USA Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 35. USA Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 36. USA Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 37. Canada Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 38. Canada Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 39. Canada Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 40. Germany Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 41. Germany Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 42. Germany Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 43. France Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 44. France Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 45. France Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 46. U.K. Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 47. U.K. Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 48. U.K. Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 49. Italy Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 50. Italy Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 51. Italy Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 52. Netherlands Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 53. Netherlands Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 54. Netherlands Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 55. Nordic Countries Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 56. Nordic Countries Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 57. Nordic Countries Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 58. China Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 59. China Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 60. China Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 61. Japan Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 62. Japan Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 63. Japan Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 64. South Korea Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 65. South Korea Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 66. South Korea Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 67. Southeast Asia Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 68. Southeast Asia Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 69. Southeast Asia Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 70. India Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 71. India Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 72. India Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 73. Australia Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 74. Australia Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 75. Australia Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 76. Mexico Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 77. Mexico Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 78. Mexico Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 79. Brazil Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 80. Brazil Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 81. Brazil Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 82. Turkey Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 83. Turkey Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 84. Turkey Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 85. Saudi Arabia Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 86. Saudi Arabia Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 87. Saudi Arabia Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 88. UAE Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 89. UAE Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 90. UAE Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 91. Years Considered
Figure 92. Research Process
Figure 93. Key Executives Interviewed
Figure 1. Nuclear Medicine Product Picture
Figure 2. Global Nuclear Medicine Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Nuclear Medicine Market Size (2019-2030) & (US$ Million)
Figure 4. Global Nuclear Medicine Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Tc-99 Picture
Figure 8. I-123/131 Picture
Figure 9. In-111 Picture
Figure 10. Xe-133 Picture
Figure 11. Th-201 Picture
Figure 12. Ga-67 Picture
Figure 13. Others Picture
Figure 14. Global Nuclear Medicine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Nuclear Medicine Sales Value Share 2019 VS 2023 VS 2030
Figure 16. Global Nuclear Medicine Sales Value Share by Type (2019-2030)
Figure 17. Diagnostic Picture
Figure 18. Therapeutic Picture
Figure 19. Global Nuclear Medicine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global Nuclear Medicine Sales Value Share 2019 VS 2023 VS 2030
Figure 21. Global Nuclear Medicine Sales Value Share by Application (2019-2030)
Figure 22. Global Nuclear Medicine Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 23. Global Nuclear Medicine Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 24. North America Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 25. North America Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 26. Europe Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 27. Europe Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Asia-Pacific Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 30. Latin America Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 31. Latin America Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 32. Middle East & Africa Nuclear Medicine Sales Value (2019-2030) & (US$ Million)
Figure 33. Middle East & Africa Nuclear Medicine Sales Value Share by Country (%), 2023 VS 2030
Figure 34. USA Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 35. USA Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 36. USA Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 37. Canada Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 38. Canada Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 39. Canada Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 40. Germany Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 41. Germany Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 42. Germany Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 43. France Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 44. France Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 45. France Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 46. U.K. Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 47. U.K. Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 48. U.K. Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 49. Italy Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 50. Italy Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 51. Italy Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 52. Netherlands Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 53. Netherlands Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 54. Netherlands Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 55. Nordic Countries Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 56. Nordic Countries Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 57. Nordic Countries Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 58. China Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 59. China Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 60. China Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 61. Japan Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 62. Japan Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 63. Japan Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 64. South Korea Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 65. South Korea Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 66. South Korea Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 67. Southeast Asia Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 68. Southeast Asia Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 69. Southeast Asia Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 70. India Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 71. India Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 72. India Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 73. Australia Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 74. Australia Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 75. Australia Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 76. Mexico Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 77. Mexico Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 78. Mexico Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 79. Brazil Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 80. Brazil Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 81. Brazil Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 82. Turkey Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 83. Turkey Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 84. Turkey Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 85. Saudi Arabia Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 86. Saudi Arabia Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 87. Saudi Arabia Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 88. UAE Nuclear Medicine Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 89. UAE Nuclear Medicine Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 90. UAE Nuclear Medicine Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 91. Years Considered
Figure 92. Research Process
Figure 93. Key Executives Interviewed
